Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. حسب William C. Barley (8915282)

الموضوعات:

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. حسب Udaysankar Chockanathan (18510288)

"…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …"

Task variability/correlations decrease independently of mean task activity removal step in fMRI data. حسب Takuya Ito (57473)

HRV parameters at different time points. حسب Shiying Liu (1569478)

الموضوعات:

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. حسب Katherine Schubert (5452712)

The levels of NF-κB related inflammatory factors, TERT expression and telomerase relative length are significantly increased in the ovarian tissue of PCOS rats. حسب Haoxuan Xue (19949764)

Transcripts with increased translation efficiency during GSC to DGC transition have a significant loss in m6A methylation. حسب John P. Zepecki (10271291)

"…Change in TE rank obtained by measuring degree of change in TE of individual transcripts between their respective GSC and DGC state and then ranking the transcripts accordingly (ranges from highest rank: greatest increase in TE with transition; to lowest rank: most decrease in TE). C) Percent composition of top 30% transcripts with most significant change in TE based on m6A status in individual samples (gain/unchanged/loss). …"

Divergence from transmitted/founder (TF) virus increases during ART-naïve infection and decreases on treatment. حسب Kelsie Brooks (8928044)

Summary of post-treatment disease course measures from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. حسب Filip Stanicic (17808254)

الموضوعات:

Disease course measures after the PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from MDMA-AT publications. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from off-label medications clinical trials. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

Summary of clinical efficacy of relevant PTSD treatments. حسب Filip Stanicic (17808254)

الموضوعات: